Glaukos, which sells micro-scale surgical devices for treating glaucoma, raised $108 million by offering 6 million shares at $18, above the upwardly revised range of $16 to $17. The company had initially filed to offer 5.4 million shares at a range of $13-$15 before updating its terms on Tuesday. At its offer price, Glaukos commands a fully diluted market cap of $628 million. It will list on the NYSE under the symbol GKOS. J.P. Morgan, BofA Merrill Lynch and Goldman Sachs acted as lead managers on the deal.
